According to Piper Jaffray, Exelixis EXEL Overweight rating is maintained
Piper Jaffray said that abstracts were published last night for the upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago from June 3rd-7th. “Exelixis has 3 oral presentations at ASCO including an overall update of the Phase II randomized discontinuation trial (RDT), the full CRPC cohort on 168 patients and additional ovarian cancer data. Exelixis will host an Investor Briefing at ASCO on Monday June 6th. The company is conducting 150-patient non-randomized extension studies in castrate-resistant prostate cancer (CRPC) and intends to initiate a randomized study using a composite endpoint in CRPC under an SPA this year. We still expect pivotal Medullary Thyroid Cancer (MTC) data this quarter potentially offering the first approval for Cabo in 2012.”
Exelixis closed yesterday at $11.66.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsExelixis Inc.Health CareLife Sciences Tools & ServicesPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in